| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_916075766043ce900399a4c2eee9f054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2ca2e4410855da087e11bf3eea8933fa |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-2821 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6896
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-46 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-577
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18 |
| filingDate |
2009-09-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b2880de3ffe25d15b89d2563e0c11d66
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3c4c50533355e7887bffbdaac5e4d3d0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_35b191b61604cf694d2970ffaba10faa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d559ae079744d96fdaef00dd3d081e2b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a0c58b9ca668f0845e61e41681ad0d0f |
| publicationDate |
2010-02-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2010044078-A |
| titleOfInvention |
Assay method for Alzheimer's disease |
| abstract |
An assay is provided that enables diagnosis of pre-onset and clinical Alzheimer's disease. The test assesses amyloid β (Aβ) peptide levels after administration of an anti-Aβ antibody to a subject. Diagnostic tests for pre-onset and clinical Alzheimer's disease are based on plasma levels of Aβ 40 , Aβ 42 , their ratio or their rate of entry after administration of antibodies that isolate Aβ. A change from the control value of any of these parameters identifies pre-onset or clinical Alzheimer's disease. [Selection figure] None |
| priorityDate |
2001-08-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |